Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Sarilumab · Kevzara, REGN-88

Monoclonal antibody · Antagonist of Interleukin-6 receptor alpha (IL6R) · developed by Sanofi Synthelabo

Approved FDA, May 2017
SNY Developer

What is Sarilumab?

Sarilumab is an interleukin-6 receptor antagonist that binds both soluble and membrane-bound IL-6 receptors and inhibits IL-6-mediated signaling. It is studied in advanced solid tumors.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Kevzara, REGN-88, SAR-153191
Drug type
Monoclonal antibody
Targets
Interleukin-6 receptor alpha (IL6R)
Mechanism
Antagonist of Interleukin-6 receptor alpha (IL6R)
Pathways
IL-6 signaling
Therapy area
Immunology, Oncology
Developer
Sanofi Synthelabo (SNY)
Also in trials of
REGN
FDA status
Approved as Kevzara (May 22, 2017), BLA761037 · FDA label
UNII
NU90V55F8I

✅ FDA-approved uses

From the indications section of the FDA label (version of Feb 27, 2026). Read the full label for the exact wording, limitations and safety information.

Conditions studied

Any Advanced Solid Tumors

More from Sanofi Synthelabo

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the SNY page.

Follow SNY, the company behind Sarilumab

See SNY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

SNY catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.